News

Inflammasome Inhibitors: The Next Generation of Innovative Immunotherapy Agents

Health
0 min read

Inflammasome Inhibitors: The Next Generation of Innovative Immunotherapy Agents

Recent breakthroughs in regulating inflammasomes will be discussed by experts on the leading edge of new discovery and therapies. Inflammatory disorders, including Alzheimer’s, inflammatory bowel disease, multiple sclerosis, Crohn’s, non-alcoholic fatty liver disease, chronic kidney disease, lupus, diabetes, and cancer, affect 5-7% of Western populations. The companies represented on this panel could potentially translate current research into future treatments.

  • Paul Ashton, PhD., Co-Founder & CEO of Inflammasome Therapeutics, Inc.
  • Gary Glick, PhD., Co-Founder & Executive Chairman of IFM Therapeutics and Michigan Professor of Chemistry
  • Steve Glover, Co-Founder, President & CEO of Zyversa Therapeutics, Inc.
  • Robert W. Keane, PhD., Professor Physiology & Biophysics, Neurological Surgery & Microbiology, and Immunology at the University of Miami, and co-founder of InflamaCore, LLC
  • Clay B. Thorp, General Partner at Hatteras Venture Partners
Share

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.